Skip to main content

Advertisement

Table 1 Multivariate analysis of MTX failure

From: Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Variable Multivariate Cox analysisa Multivariate competing risks analysisb
Reason for MTX failure Reason for MTX failure
Adverse event (N = 67) Inefficacy (N = 143) Adverse event (N = 67) Inefficacy (N = 143)
Age of disease onset NR 0.97 (0.96, 0.99) p < 0.001 NR 0.97 (0.96, 0.99) p < 0.001
Female gender 1.39 (0.82, 2.35) p = 0.221 1.34 (0.90, 1.99) p = 0.143 1.28 (0.78, 2.14) p = 0.325 1.23 (0.83, 1.40) p = 0.298
BMI NR 1.02 (0.99, 1.05) p = 0.182 NR 1.02 (0.99, 1.05) p = 0.184
Current smoker NR 1.41 (0.86, 2.32) p = 0.176 NR 1.43 (0.88, 2.36) p = 0.150
Symptom duration NR 1.00 (1.00, 1.00) p = 0.174 NR 1.00 (1.00, 1.00) p = 0.120
HAQ score at baseline 1.39 (0.98, 1.96) p = 0.064 1.15 (0.88, 1.49) p = 0.314 1.34 (0.96, 1.86) p = 0.092 1.07 (0.82, 1.40) p = 0.606
DAS-28(CRP) at baseline NR 1.27 (1.10, 1.47) p = 0.001 NR 1.23 (1.05, 1.43) p = 0.008
Shared epitope homozygosity NR 1.44 (0.81, 2.58) p = 0.214 NR 1.42 (0.79, 2.56) p = 0.235
Rheumatoid factor positivity 0.37 (0.21, 0.64) p < 0.001 1.44 (0.98, 2.13) p = 0.064 0.34 (0.20, 0.59) p < 0.001 1.67 (1.13, 2.48) p = 0.011
ACPA positivityc NR NR NR NR
  1. NR not reported, BMI body mass index, HAQ, Health Assessment Questionnaire, DAS-28(CRP) disease activity score-28-C-reactive protein, ACPA anti-citrullinated protein antibody
  2. aValues are HR (95% CI)
  3. bValues are exponentiated coefficients (exp(beta); subdistribution hazard ratio (sHR)). (95% CI)
  4. cIncluded in univariate model only. Bold values represent P < 0.05